UBS Maintains a 'Buy' on Cisco (CSCO); Strong 2Q Execution, Outperforming Comps
CSCO Hot Sheet
Rating Summary:25 Buy, 18 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 7 | New: 23
UBS maintains a 'Buy' on Cisco (NASDAQ: CSCO) price target raised from $23 to $24.
UBS analyst says, "2Q revs and EPS beat investor expectations. Cisco’s order pipeline was healthy growing 7% YoY with a B2B of 1...CSCO again defied service provider capital spending gravity with total SP orders +12% YoY, leading customer order growth for the 3rd quarter running."
"We tweak our CY12 and CY13 sales and EPS fcsts higher to $47.4B (+6%) and $1.87 and $50.8B (+7%) and $2.02 from $46.5B and $1.81 and $49.9B and $1.96. Cisco generated $2.8B in FCF in 2Q, raised its qtrly dividend to $0.08 per shr, and we expect M&A to become a new priority. Total cash of ~$46.7B (~$5B in US)."
For an analyst ratings summary and ratings history on Cisco click here. For more ratings news on Cisco click here.
Shares of Cisco closed at $20.43 yesterday, with a 52 week range of $13.30-$22.15.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
UBS analyst says, "2Q revs and EPS beat investor expectations. Cisco’s order pipeline was healthy growing 7% YoY with a B2B of 1...CSCO again defied service provider capital spending gravity with total SP orders +12% YoY, leading customer order growth for the 3rd quarter running."
"We tweak our CY12 and CY13 sales and EPS fcsts higher to $47.4B (+6%) and $1.87 and $50.8B (+7%) and $2.02 from $46.5B and $1.81 and $49.9B and $1.96. Cisco generated $2.8B in FCF in 2Q, raised its qtrly dividend to $0.08 per shr, and we expect M&A to become a new priority. Total cash of ~$46.7B (~$5B in US)."
For an analyst ratings summary and ratings history on Cisco click here. For more ratings news on Cisco click here.
Shares of Cisco closed at $20.43 yesterday, with a 52 week range of $13.30-$22.15.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Needham & Company Reiterates a 'Buy' on NetApp (NTAP); Solid 4Q Overshadowed by Conservative 1Q
- UBS Maintains a 'Neutral' on Ralcorp Holdings (RAH); Trimming Numbers After Q2 Miss
- Wells Fargo Upgrades Watson Pharmaceuticals (WPI) to Outperform; Actavis Acquisition Adds Growth Prospects
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
UBS, DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
